{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:06:44Z","timestamp":1780315604704,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,2,7]],"date-time":"2015-02-07T00:00:00Z","timestamp":1423267200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s10157-015-1086-2","type":"journal-article","created":{"date-parts":[[2015,2,5]],"date-time":"2015-02-05T22:18:17Z","timestamp":1423174697000},"page":"867-877","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial"],"prefix":"10.1007","volume":"19","author":[{"given":"Satoru","family":"Muto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Higashihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Ubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Horie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,7]]},"reference":[{"key":"1086_CR1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1159\/000045214","volume":"80","author":"E Higashihara","year":"1998","unstructured":"Higashihara E, Nutahara K, Kojima N, et al. Prevalence and renal prognosis of diagnosed Autosomal-dominant polycystic kidney disease in Japan. Nephron. 1998;80:421\u20137.","journal-title":"Nephron."},{"key":"1086_CR2","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1046\/j.1523-1755.2000.00250.x","volume":"58","author":"M Levy","year":"2000","unstructured":"Levy M, Feingold J. Estimating prevalence in single-gene kidney diseases progressing to renal failure. Kidney Int. 2000;58:925\u201343.","journal-title":"Kidney Int."},{"key":"1086_CR3","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ki.2011.465","volume":"81","author":"CR Parikh","year":"2012","unstructured":"Parikh CR, Dahl NK, Chapman AB, et al. Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int. 2012;81:784\u201390.","journal-title":"Kidney Int."},{"key":"1086_CR4","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","volume":"354","author":"JJ Grantham","year":"2006","unstructured":"Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med. 2006;354:2122\u201330.","journal-title":"N Engl J Med."},{"key":"1086_CR5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/ng0695-151","volume":"10","author":"J Hughes","year":"1995","unstructured":"Hughes J, Ward CJ, Peral B, et al. The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains. Nat Genet. 1995;10:151\u201360.","journal-title":"Nat Genet."},{"key":"1086_CR6","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.272.5266.1339","volume":"272","author":"T Mochizuki","year":"1996","unstructured":"Mochizuki T, Wu G, Hayashi T, et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science. 1996;272:1339\u201342.","journal-title":"Science."},{"key":"1086_CR7","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1053\/j.ajkd.2010.11.029","volume":"57","author":"VE Torres","year":"2011","unstructured":"Torres VE, Meijer E, Bae KT, et al. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3\u20134 study. Am J Kidney Dis. 2011;57:692\u20139.","journal-title":"Am J Kidney Dis."},{"key":"1086_CR8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2147\/TCRM.S1617","volume":"4","author":"A Masoumi","year":"2008","unstructured":"Masoumi A, Reed-Gitomer B, Kelleher C, et al. Developments in the management of autosomal dominant polycystic kidney disease. Ther Clin Risk Manag. 2008;4:393\u2013407.","journal-title":"Ther Clin Risk Manag."},{"key":"1086_CR9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10157-012-0741-0","volume":"17","author":"T Mochizuki","year":"2013","unstructured":"Mochizuki T, Tsuchiya K, Nitta K. Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies. Clin Exp Nephrol. 2013;17:317\u201326.","journal-title":"Clin Exp Nephrol."},{"key":"1086_CR10","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","volume":"16","author":"X Wang","year":"2005","unstructured":"Wang X, Gattone V II, Harris PC, et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol. 2005;16:846\u201351.","journal-title":"J Am Soc Nephrol."},{"key":"1086_CR11","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","volume":"9","author":"VH Gattone II","year":"2003","unstructured":"Gattone VH II, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003;9:1323\u20136.","journal-title":"Nat Med."},{"key":"1086_CR12","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407\u201318.","journal-title":"N Engl J Med."},{"key":"1086_CR13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/kisup.2012.77","volume":"3","author":"The International Society of Nephrology","year":"2013","unstructured":"The International Society of Nephrology. Summary of recommendation statements. Kidney Int Suppl. 2013;3:5\u201314.","journal-title":"Kidney Int Suppl."},{"key":"1086_CR14","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis."},{"key":"1086_CR15","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","volume":"363","author":"A Serra","year":"2010","unstructured":"Serra A, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363:820\u20139.","journal-title":"N Engl J Med."},{"issue":"Suppl 1","key":"1086_CR16","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10557-011-6304-x","volume":"25","author":"M Matsuzaki","year":"2011","unstructured":"Matsuzaki M, Hori M, Izumi T, et al. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther. 2011;25(Suppl 1):S33\u201345.","journal-title":"Cardiovasc Drugs Ther."},{"key":"1086_CR17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/hepr.12098","volume":"44","author":"I Sakaida","year":"2014","unstructured":"Sakaida I, Kawazoe S, Kajimura K, et al. Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res. 2014;44:73\u201382.","journal-title":"Hepatol Res."},{"key":"1086_CR18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ki.2009.128","volume":"76","author":"VE Torres","year":"2009","unstructured":"Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 2009;76:149\u201368.","journal-title":"Kidney Int."}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-015-1086-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-015-1086-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-015-1086-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T06:44:44Z","timestamp":1559112284000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-015-1086-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,7]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["1086"],"URL":"https:\/\/doi.org\/10.1007\/s10157-015-1086-2","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,7]]}}}